Medtronic Raises Fiscal 2027 Guidance on Strong Cardiovascular Growth
Editorial responsibility
- No named human review is recorded for this page.
- Source reporting is collected, normalized, translated or condensed automatically when needed.
- Automatically published source-backed update
Medtronic raised its fiscal 2027 organic revenue growth forecast to 7.25%-7.75% from 6.75%-7.25% after reporting quarterly earnings that beat analyst expectations. The company posted adjusted earnings of $1.45 per share on revenue of $9.76 billion, driven by a 19.5% increase in cardiovascular segment sales to $3.93 billion, with pulsed field ablation products growing 88%. Management also lifted the lower end of adjusted earnings guidance to $5.94 per share. CEO Geoff Martha attributed the confidence to broad-based performance and newer platforms. However, the earnings revision was modest, and the high growth rates in cardiovascular devices may be difficult to sustain. CFO Thierry Pieton noted tariff refunds nearly covered duties paid but future offsets are uncertain. Medtronic also invested $80 million in heart-valve company Pi-Cardia with an option to acquire it for $210 million, and $700 million in Cornerstone Robotics for distribution rights to the Sentire robotic surgical system outside the U.S., carrying execution risks.
Source report
By Noor Ul Ain Rehman Wed, September 9, 2026 at 4:18 PM PDT | 4 min read
Ticker: MDT
Medtronic plc (NYSE: MDT) entered fiscal 2027 expecting solid growth. One quarter later, strong demand for its cardiovascular devices has given management enough confidence to raise that outlook.
The company increased its organic revenue growth forecast and lifted the lower end of its adjusted earnings range after beating quarterly expectations. Its cardiovascular business was the standout, helped by rapid growth in pulsed field ablation products used to treat irregular heart rhythms. Medtronic is also investing in heart-valve technology and surgical robotics to strengthen its longer-term growth portfolio.
Bull Case
Medtronic now expects fiscal 2027 organic revenue growth of between 7.25% and 7.75%, up from its previous forecast of 6.75% to 7.25%. The midpoint consequently increased from 7% to 7.5%, representing a meaningful improvement in management's expectations.
The company also raised the lower end of its adjusted earnings forecast to $5.94 per share from $5.90 while maintaining the upper end at $6. Although the profit revision is smaller, it narrows the range toward the higher end of the original outlook.
Quarterly performance helps explain the increased confidence. Medtronic reported adjusted earnings of $1.45 per share on revenue of $9.76 billion. Analysts surveyed by LSEG had expected earnings of $1.39 per share and sales of $9.55 billion.
One of the strongest drivers of momentum came from cardiovascular devices, with sales in the cardiovascular segment increasing 19.5% to $3.93 billion. The company's pulsed field ablation portfolio, which treats irregular heart rhythms, grew 88% and was a major contributor to the segment's performance.
CEO Geoff Martha said Medtronic's confidence reflects not only the quarter's strength but also the breadth of performance across its businesses and the growing contribution from newer platforms, which suggests the company's outlook is not based entirely on one established product category.
Medtronic is also deploying capital into additional growth markets:
- It agreed to invest $80 million in heart-valve repair device company Pi-Cardia and received an option to acquire it for $210 million.
- In a separate development, Medtronic invested $700 million in Cornerstone Robotics and obtained rights to distribute the Sentire robotic surgical system in certain markets outside the United States.
Martha told Reuters that soft-tissue robotic surgery penetration in emerging markets remains below 1%, describing Sentire as complementary to Medtronic's Hugo system, giving the company another way to pursue an underpenetrated market.
Bear Case
The earnings guidance increase is relatively modest. Medtronic raised only the lower end by four cents while leaving the $6 upper limit unchanged. The revision signals greater confidence but does not represent a substantial increase in expected profitability.
The company's cardiovascular results also create a demanding comparison for future quarters. An 88% increase in pulsed field ablation and 19.5% cardiovascular growth may be difficult to sustain as the business becomes larger. Medtronic has not said those specific growth rates will continue.
Tariffs remain another uncertainty. Chief Financial Officer Thierry Pieton said refunds received during the quarter almost covered the duties Medtronic paid. However, the company has not included future refunds in its outlook, meaning later tariff costs may not receive the same offset.
The strategic investments carry execution risk as well:
- Medtronic must demonstrate that its $700 million Cornerstone investment and international distribution rights can translate low robotic-surgery penetration into meaningful sales.
- Likewise, the Pi-Cardia investment and acquisition option do not guarantee regulatory progress or commercial adoption for its technology.
Finally, management's emphasis on acquisitions in higher-growth medtech categories requires careful capital allocation.
Source
Yahoo FinanceWestern